#China #Beijing #Cancer Treatment #Concord Medical #Proton Therapy

Concord Medical Reports Financial Results for the First Half of 2025

Concord Medical Services Holdings Limited, often referred to as Concord Medical, is a prominent healthcare provider focused on oncology, particularly cancer treatment and research, in China. On September 26, 2025, the company disclosed its unaudited financial results for the first six months of the year.

Financial Highlights of H1 2025

In the first half of 2025, Concord Medical generated a total net revenue of RMB200.6 million (approximately $28.0 million), which reflects an 8.3% decline compared to RMB218.8 million from the same period last year. The revenue breakdown shows that RMB153.0 million ($21.4 million) came from the hospital division, while RMB47.6 million ($6.6 million) was attributed to the network business.

Despite the decline in overall revenue, there were notable improvements in gross loss—the company recorded a loss of RMB4.3 million ($0.6 million) in H1 2025, a significant drop from the RMB41.6 million loss reported in H1 2024. The gross loss margin improved to 2.1%, in stark contrast to 19.0% from the previous year.

Furthermore, the net loss attributable to ordinary shareholders was RMB27.1 million ($3.8 million) in the first half of 2025, down from RMB172.3 million in the previous year. Consequently, the basic and diluted loss per share for both Class A and Class B shares stood at RMB0.21 ($0.03), significantly better than RMB1.31 from H1 2024. The Adjusted EBITDA for this period was recorded at negative RMB62.2 million ($8.7 million), improving from negative RMB148.0 million.

Proton Therapy Advancements

Dr. Jianyu Yang, Concord Medical's Chairman and CEO, remarked on the increasing role of proton therapy in cancer treatment. This advanced radiation therapy is praised for its precision, reducing harmful side effects typically associated with traditional methods. The significant clinical advancements at Guangzhou Concord Cancer Hospital, the first proton therapy center in South mainland China, include tailored treatment protocols for various cancers.

In treating nasopharyngeal carcinoma, notable tumor regression has been observed among patients aged 10 to 71 years. Elderly patients experienced only mild adverse reactions, indicating the efficacy of the treatment across diverse age groups. Moreover, for central nervous system tumors, the hospital has successfully ensured functional preservation, particularly in complex cases requiring treatments that span the entirety of the brain and spine.

Proton therapy has demonstrated its potential in pediatric care as well, with the hospital successfully treating its youngest patient, a child just above one year old. This intricate balance of effective treatment with minimal risk underscores the hospital’s commitment to enhancing patient safety and outcomes.

Looking Ahead

As Concord Medical continues to focus on patient-centered care, it aims to expand public awareness about the benefits of precision radiotherapy. The company is dedicated to improving patients' access to cutting-edge diagnostic tools, therapies, and innovative medications—all while reinforcing the importance of comprehensive care in the fight against cancer. The management reaffirmed its commitment to delivering advanced oncology services across its network of hospitals and clinics throughout China.

In summary, while facing challenges in revenue streams particularly within the network business due to macroeconomic conditions, Concord Medical's strategic focus on enhancing operational efficiency, alongside expanding its proton therapy services, marks a pivotal step in advancing cancer treatment services in China. With a clear emphasis on innovation and quality care, the outlook for Concord Medical remains positive as it navigates the evolving healthcare landscape.

For more information, please visit Concord Medical’s official site.